Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12280089

Dry powder formulation of caveolin-1 peptides and methods of use thereof

The Board of Regents of the University of Texas System · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280055

Combination therapies

Mirati Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280063

Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer'

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280108

Vaccines having an antigen and interleukin-21 as an adjuvant

Inovio Pharmaceuticals, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281327

Lymphohematopoietic engineering using CAS9 base editors

Regents of the University of Minnesota · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281140

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Enanta Pharmaceuticals, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280113

Ras inhibitors

Revolution Medicines, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280029

Methods of treatment of inflammation related conditions using pluripotent anti-inflammator

INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280037

Method and pharmaceutical composition for treating or preventing trichomoniasis and uses t

EVOFEM BIOSCIENCES, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280140

Processes for production of tumor infiltrating lymphocytes and uses of the same in immunot

Iovance Biotherapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280124

Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281164

Genetically engineered dual-targeting chimeric antigen receptor and use thereof

WEST CHINA HOSPITAL, SICHUAN UNIVERSITY · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281056

Methods for making and using endoxifen

ATOSSA THERAPEUTICS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12279630

Treatment and prevention of seed allergies

TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280032

Methods and compositions for increasing the potency of antifungal agents

PACIFIC NORTHWEST RESEARCH INSTITUTE · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280046

Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease

CRINETICS PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280149

Manufacturing of bupivacaine multivesicular liposomes

Pacira Pharmaceuticals, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281329

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281021

System and method for making boron oxide nanoparticles

The Regents of the University of California · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280057

Vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promot

SOUTH DAKOTA BOARD OF REGENTS · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281073

Substituted piperidine compound and use thereof

Takeda Pharmaceutical Company Limited · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280159

Therapeutic protein-based nanoparticles for treating cancer

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280093

Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280142

Compositions for preventing infection

Altamira Medica AG · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted